tiprankstipranks
Trending News
More News >

Clene Faces Nasdaq Delisting Risk Amid Regulatory Pursuits

Story Highlights
  • Clene Inc. risks Nasdaq delisting if market value isn’t improved by November 3, 2025.
  • Clene plans a New Drug Application for CNM-Au8 in ALS, supported by promising survival data.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Clene Faces Nasdaq Delisting Risk Amid Regulatory Pursuits

Confident Investing Starts Here:

Clene ( (CLNN) ) has shared an announcement.

On May 6, 2025, Clene Inc. received a notice from Nasdaq indicating that its market value of listed securities had fallen below the required $35 million for 30 consecutive business days, risking delisting if not rectified by November 3, 2025. Meanwhile, Clene is actively pursuing regulatory milestones, including a planned New Drug Application for CNM-Au8 in ALS, supported by recent data showing improved survival rates in ALS patients. The company is also preparing for discussions with the FDA regarding its neurofilament light chain biomarker data and has reported financial results showing a net loss decrease compared to the previous year.

Spark’s Take on CLNN Stock

According to Spark, TipRanks’ AI Analyst, CLNN is a Underperform.

Clene’s stock score of 39 reflects significant financial distress with declining revenues, high net losses, and negative equity, making it high-risk. Technical indicators suggest a bearish trend, further compounding investor concerns. While recent corporate announcements about advancements in neurological treatments provide a slight positive outlook, they are insufficient to offset the company’s broader financial challenges.

To see Spark’s full report on CLNN stock, click here.

More about Clene

Clene Inc., along with its subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS). The company is based in Salt Lake City, Utah, with research and development and manufacturing operations in Maryland. Clene’s primary product, CNM-Au8, is an investigational therapy that enhances neuronal health and function by targeting mitochondrial function and the NAD pathway.

Average Trading Volume: 53,307

Technical Sentiment Signal: Sell

Current Market Cap: $25.36M

For a thorough assessment of CLNN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App